Impact of Antipsychotic Medications on Weight Gain and Eating
                    Disorder-Related Psychopathology in Adult Inpatients with Anorexia
                    Nervosa

Tabea Bauman; David R. Kolar; Christoph U. Correll; Verena Haas; Ulrich Voderholzer

doi:10.1055/a-2436-9552

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2025; 58(02): 80-87
DOI: 10.1055/a-2436-9552

Original Paper

Impact of Antipsychotic Medications on Weight Gain and Eating Disorder-Related Psychopathology in Adult Inpatients with Anorexia Nervosa

Authors

Tabea Bauman

¹Schoen Clinic Roseneck, Prien am Chiemsee, Germany
David R. Kolar

²Clinical Child and Adolescent Psychology and Psychotherapy, Department of Psychology, University of Regensburg, Regensburg, Germany

³Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany
Christoph U. Correll

⁴Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany

⁵Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA

⁶Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York, USA

⁷Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York, USA
Verena Haas

⁴Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany
Ulrich Voderholzer

¹Schoen Clinic Roseneck, Prien am Chiemsee, Germany

³Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany

⁸Department of Psychiatry and Psychotherapy, University Hospital of Freiburg, Freiburg, Germany

Abstract

Introduction The impact of antipsychotic use on weight gain and eating disorder-related psychopathology in adult inpatients with anorexia nervosa (AN) is unclear.

Methods Consecutively hospitalized adults with AN were retrospectively analyzed. Co-primary outcomes were body mass index (BMI) and weekly weight change. Secondary outcomes were Eating Disorder Inventory-2 (EDI-2) subscale scores ‘drive for thinness’ and ‘body dissatisfaction’. Admission-to-discharge changes were compared in patients continuing pre-admission antipsychotics (APcont), starting antipsychotics (APnew) and patients without psychopharmacotherapy (noMed) using linear mixed models. Sensitivity analyses were conducted in subgroups matched for age, length of stay, baseline BMI and baseline EDI-2 scores. Subgroups were also compared regarding BMI trajectories, using non-linear growth curve models. Within-group analyses compared weight gain before vs. after the median antipsychotic onset week.

Results Of 775 adult inpatients (mean length of stay =103.5±48.0 days), 21.7% received antipsychotics (APcont =7.7%; APnew=13.9%), i. e., olanzapine (n=127, dose =5.5±3.1 mg/day) or quetiapine (n=41, dose=100.0±97.7 mg/day), while 78.3% did not receive any medication. Comparing all three groups, a significant time×group interaction was found for noMed and APnew vs. APcont (p=0.011), but this effect disappeared when comparing matched subgroups. However, in matched subgroups (n=54 each) APnew showed steeper weight gain vs. APcont both overall (p=0.011) and after median antipsychotic initiation (5.8±5.0 weeks) (p≤0.001). No significant group differences emerged in EDI-2 subscale scores.

Discussion In this naturalistic study, 22% of adult inpatients received antipsychotics. However, neither weight gain nor AN-related psychopathology changed differently in patients treated with vs. without antipsychotics. Newly initiated antipsychotic treatment vs. continuation from pre-admission had better weight gain outcomes.

Keywords

anorexia nervosa - adults - inpatients - weight gain - antipsychotics

Volltext

Referenzen

References
1 Solmi M, Radua J, Olivola M. et al. Age at onset of mental disorders worldwide: Large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry 2022; 27: 281-295
2 Treasure J, Zipfel S, Micali N. et al. Anorexia nervosa. Nat Rev Dis Primers 2015; 1: 15074
3 Grosser J, Hofmann T, Stengel A. et al. Psychological and nutritional correlates of objectively assessed physical activity in patients with anorexia nervosa. Eur Eat Disord Rev 2020; 28: 559-570
4 Lehmann CS, Hofmann T, Elbelt U. et al. The role of objectively measured, altered physical activity patterns for body mass index change during inpatient treatment in female patients with anorexia nervosa. J Clin Med 2018; 7: 289
5 Solmi M, Monaco F, Højlund M. et al. Outcomes in people with eating disorders: A transdiagnostic and disorder-specific systematic review, meta-analysis and multivariable meta-regression analysis. World Psychiatry 2024; 23: 124-138
6 Chan JKN, Correll CU, Wong CSM. et al. Life expectancy and years of potential life lost in people with mental disorders: A systematic review and meta-analysis. eClinicalMedicine 2023; 65: 102294
7 Koerner T, Haas V, Heese J. et al. Outcomes of an accelerated inpatient refeeding protocol in 103 extremely underweight adults with anorexia nervosa at a specialized clinic in Prien, Germany. J Clin Med 2020; 9: 1535
8 Haas V, Kohn M, Körner T. et al. Practice-based evidence and clinical guidance to support accelerated re-nutrition of patients with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2021; 60: 555-561
9 Monteleone AM, Pellegrino F, Croatto G. et al. Treatment of eating disorders: A systematic meta-review of meta-analyzes and network meta-analyzes. Neurosci Biobehav Rev 2022; 142: 104857
10 Herpertz S, Fichter M, Herpertz-Dahlmann B. et al. Gemeinsame S3-Leitlinie ”Diagnostik und therapie der essstörungen” [Joint German Guideline “Diagnosis and treatment of eating disorders”]. Berlin: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF); 2018
11 National Guideline Alliance (UK). Eating disorders: Recognition and treatment. London: National Institute for Health and Care Excellence (NICE); 2017. updated 2020
12 Crone C, Fochtmann LJ, Attia E. et al. The American Psychiatric Association Practice Guideline for the treatment of patients with eating disorders. Am J Psychiatry 2023; 180: 167-171
13 Himmerich H, Lewis YD, Conti C. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry 2023; 24: 1-64
14 Bak M, Fransen A, Janssen J. et al. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS One 2014; 9: e94112
15 Bissada H, Tasca GA, Barber AM. et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165: 1281-1288
16 Attia E, Kaplan AS, Walsh BT. et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011; 41: 2177-2182
17 Brambilla F, Garcia CS, Fassino S. et al. Olanzapine therapy in anorexia nervosa: Psychobiological effects. Int Clin Psychopharmacol 2007; 22: 197-204
18 Kafantaris V, Leigh E, Hertz S. et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011; 21: 207-212
19 Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev 2012; 20: 331-334
20 Attia E, Steinglass JE, Walsh BT. et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: A randomized clinical trial. Am J Psychiatry 2019; 176: 449-456
21 Kishi T, Kafantaris V, Sunday S. et al. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: e757-e766
22 Lebow J, Sim LA, Erwin PJ. et al. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: A systematic review and meta-analysis. Int J Eat Disord 2013; 46: 332-339
23 de Vos J, Houtzager L, Katsaragaki G. et al. Meta-analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa. J Eat Disord 2014; 2: 27
24 Dold M, Aigner M, Klabunde M. et al. Second-generation antipsychotic drugs in anorexia nervosa: A meta-analysis of randomized controlled trials. Psychother Psychosom 2015; 84: 110-116
25 Han R, Bian Q, Chen H. Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta-analysis. Brain Behav 2022; 12: e2498
26 Barbarich NC, McConaha CW, Gaskill J. et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 2004; 65: 1480-1482
27 Bosanac P, Kurlender S, Norman T. et al. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 2007; 22: 223-230
28 Resmark G, Herpertz S, Herpertz-Dahlmann B. et al. Treatment of anorexia nervosa-new evidence-based guidelines. J Clin Med 2019; 8: 153
29 Watanabe N, Omori IM, Nakagawa A. et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: Systematic review and meta-analysis. CNS Drugs 2010; 24: 35-53
30 Pillinger T, Howes OD, Correll CU. et al. Antidepressant and antipsychotic side-effects and personalised prescribing: A systematic review and digital tool development. Lancet Psychiatry 2023; 10: 860-876
31 Garner DM. Eating Disorder Inventory-2: Professional Manual. Psychological Assessment Resources. 1991
32 Paul T, Thiel A. Eating Disorder Inventory-2: Deutsche Version. Hogrefe Verlag; 2005
33 R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2021
34 Pinheiro J, Bates D, DebRoy S. et al. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1–153
35 Ho D, Imai K, King G. et al. MatchIt: Nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42: 1-28
36 Mirman D. Growth Curve Analysis and Visualization Using R. Chapman and Hall; 2014
37 Bates D, Mächler M, Bolker B. et al. Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67: 1-48
38 Frank B, Arnold S, Jaite C. et al. Antipsychotic effects on anthropometric outcomes in anorexia nervosa: A retrospective chart review of hospitalized children and adolescents. J Eat Disord 2023; 11: 151
39 Solmi M, Murru A, Pacchiarotti I. et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13: 757-777
40 Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17: 97-107
41 De Young K, Bottera A, Kambanis E. et al. Delusional intensity as a prognostic indicator among individuals with severe to extreme anorexia nervosa hospitalized at an acute medical stabilization program. Int J Eat Disord 2022; 55: 215-222
42 Pruccoli J, Bergonzini L, Pettenuzzo I. et al. The role of risperidone in the treatment of children and adolescents with anorexia nervosa. J Psychopharmacol 2023; 37: 545-553
43 Hagman J, Gralla J, Sigel E. et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. J Am Acad Child Adolesc Psychiatry 2011; 50: 915-924
44 Tahıllıoğlu A, Özcan T, Yüksel G. et al. Is aripiprazole a key to unlock anorexia nervosa?: A case series. Clin Case Rep 2020; 8: 2827-2834
45 Frank GK, Shott ME, Hagman JO. et al. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord 2017; 50: 447-450